Boehringer, Click DTx for schizophrenia clears pivotal trial Boehringer Ingelheim and Click Therapeutics have revealed the data behind their pivotal trial of a digital therapeutic for schizophrenia.

#Boehringer #ClickDTx #schizophrenia #mentalhealth #psychiatry #BoehringerIngelheim #ECNP #phase3 #CONVOKEtrial #CT155 #CAINSMAP #interactivepsychosocialintervention #antipsychoticdrugtreatment #prescriptiondigitaltherapeutics #breakthroughdevicestatus #FDA
zurl.co/OXeAl

Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app

#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD